Deciphering lung adenocarcinoma evolution: Integrative s ingle‐cell genomics identifies the prognostic lung progression associated signature
Journal of Cellular and Molecular Medicine · 2024-06 · 28 (11)
DOI: 10.1111/jcmm.18408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 04.06.2024. Verfasst von Pengpeng Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy,…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Disease Progression, Single-Cell Analysis, Lung Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Tianjin Municipality.
Abstract (Originalsprache)
We employed single‐cell analysis techniques, specifically the inferCNV method, to dissect the complex progression of lung adenocarcinoma (LUAD) from adenocarcinoma in situ (AIS) through minimally invasive adenocarcinoma (MIA) to invasive adenocarcinoma (IAC). This approach enabled the identification of Cluster 6, which was significantly associated with LUAD progression. Our comprehensive analysis included intercellular interaction, transcription factor regulatory networks, trajectory analysis, and gene set variation analysis (GSVA), leading to the development of the lung progression associated signature (LPAS). Interestingly, we discovered that the LPAS not only accurately predicts the prognosis of LUAD patients but also forecasts genomic alterations, distinguishes between ‘cold’ and ‘hot’ tumours, and identifies potential candidates suitable for immunotherapy. PSMB1, identified within Cluster 6, was experimentally shown to significantly enhance cancer cell invasion and migration, highlighting the clinical relevance of LPAS in predicting LUAD progression and providing a potential target for therapeutic intervention. Our findings suggest that LPAS offers a novel biomarker for LUAD patient stratification, with significant implications for improving prognostic accuracy and guiding treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical Univer…
- Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Pengpeng Zhang, Zhenfa Zhang, Jun Fan
Förderung
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Zhang, P., Yang, Z., Liu, Z., Zhang, G., Zhang, L., Zhang, Z., & Fan, J. (2024). Deciphering lung adenocarcinoma evolution: Integrative s ingle‐cell genomics identifies the prognostic lung progression associated signature. Journal of Cellular and Molecular Medicine, 28(11). https://doi.org/10.1111/jcmm.18408
Vancouver
Zhang P, Yang Z, Liu Z, Zhang G, Zhang L, Zhang Z, et al. Deciphering lung adenocarcinoma evolution: Integrative s ingle‐cell genomics identifies the prognostic lung progression associated signature. Journal of Cellular and Molecular Medicine. 2024;28(11). doi:10.1111/jcmm.18408
BibTeX
@article{Zhang2024,
author = {Zhang, Pengpeng and Yang, Zijun and Liu, Zuo and Zhang, Ge and Zhang, Lianmin and Zhang, Zhenfa and Fan, Jun},
title = {Deciphering lung adenocarcinoma evolution: Integrative s ingle‐cell genomics identifies the prognostic lung progression associated signature},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {11},
doi = {10.1111/jcmm.18408}
}
EUVIMED